Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia

October 5th 2020


Bone Therapeutics grants exclusive license to Link Health and Pregene for the development and commercialization of ALLOB in Greater China and a number of other major Asian countries. Terms include €55 million in total upfront and milestone payments with €10 million expected in next 24 months as well as tiered double-digit royalties on net sales. Please discorver the press relaese here.